Intuitive Surgical (ISRG)
NASDAQ:ISRG
Want to see ISRG full AI Analyst Report?
ISRG Stock Chart & Stats
$469.21
$11.55(2.17%)
At close: 4:00 PM EST
$469.21
$11.55(2.17%)
Day’s Range― - ―
52-Week Range$427.84 - $603.88
Previous CloseN/A
Volume485.62K
Average Volume (3M)1.68M
Market Cap
$159.39B
Enterprise Value$157.36B
Total Cash (Recent Filing)$4.55B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)49.8
Beta1.07
Next Earnings
Jul 16, 2026EPS Estimate
2.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.37
Shares Outstanding354,162,840
10 Day Avg. Volume1,874,960
30 Day Avg. Volume1,676,593
Financial Highlights & Ratios
PEG Ratio3.17
Price to Book (P/B)11.34
Price to Sales (P/S)20.08
P/FCF Ratio81.16
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue14.87
Enterprise Value/Gross Profit22.43
Enterprise Value/Ebitda41.86
Forecast
1Y Price Target
$576.53Price Target Upside22.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
EPS Forecast (FY)10.38
Revenue Forecast (FY)$11.68B
Bulls Say, Bears Say
Bulls Say
Acquisition And Imaging PipelineAcquisition of a robotic biopsy and AI tissue-assessment business plus advances in dye-free tissue oxygenation imaging could enable new intraoperative decision-support tools across multiple disease areas and broaden the product portfolio.
Platform Adoption And Fleet ExpansionStrong adoption of the company's new-generation surgical robot platform is expected to prompt hospitals to upgrade systems and expand robotic fleets, increasing demand for systems and recurring consumables.
Procedure Expansion And Regulatory ApprovalsRegulatory clearance for additional cardiac procedures combined with expansion into appendectomy and upper gastrointestinal indications increases the range of surgeries addressable by the platform, widening the long-term procedural market.
Bears Say
International Exposure And Tariff RiskExposure to certain international markets and potential tariff impacts could slow procedure growth abroad and pressure margins outside the domestic market.
Product Recall And Regulatory ScrutinyRecall of specific stapler reloads and a regulatory alert advising customers to stop using affected products create safety and reputational risks that could reduce hospital confidence and invite additional oversight.
Valuation RiskValuation is elevated versus large-cap medical device peers, increasing sensitivity to any slowdown in growth or disappointing results that could lead to meaningful stock downside.
Intuitive Surgical News
ISRG FAQ
What was Intuitive Surgical’s price range in the past 12 months?
Intuitive Surgical lowest stock price was $427.84 and its highest was $603.88 in the past 12 months.
What is Intuitive Surgical’s market cap?
Intuitive Surgical’s market cap is $159.39B.
When is Intuitive Surgical’s upcoming earnings report date?
Intuitive Surgical’s upcoming earnings report date is Jul 16, 2026 which is in 68 days.
How were Intuitive Surgical’s earnings last quarter?
Intuitive Surgical released its earnings results on Apr 21, 2026. The company reported $2.5 earnings per share for the quarter, beating the consensus estimate of $2.122 by $0.378.
Is Intuitive Surgical overvalued?
According to Wall Street analysts Intuitive Surgical’s price is currently Undervalued.
Does Intuitive Surgical pay dividends?
Intuitive Surgical does not currently pay dividends.
What is Intuitive Surgical’s EPS estimate?
Intuitive Surgical’s EPS estimate is 2.51.
How many shares outstanding does Intuitive Surgical have?
Intuitive Surgical has 354,162,840 shares outstanding.
What happened to Intuitive Surgical’s price movement after its last earnings report?
Intuitive Surgical reported an EPS of $2.5 in its last earnings report, beating expectations of $2.122. Following the earnings report the stock price went up 7.164%.
Which hedge fund is a major shareholder of Intuitive Surgical?
Currently, no hedge funds are holding shares in ISRG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Intuitive Surgical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$576.53 (22.87% Upside)
$576.53 (22.87% Upside)
Blogger Sentiment
Bullish
ISRG Sentiment 85%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 38.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.80%
12-Months-Change
Fundamentals
Return on Equity
17.01%
Trailing 12-Months
Asset Growth
4.63%
Trailing 12-Months
Company Description
Intuitive Surgical
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
ISRG Company Deck
ISRG Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial and financial momentum: double-digit revenue and procedure growth, expanding placements and adoption of new platforms (da Vinci 5, SP, Ion), margin expansion and supportive clinical data. Headwinds were noted but largely manageable in the near term — China and Japan remain challenged, bariatric volume was down due to GLP-1 adoption, there are input-cost and tariff risks, and a contained cybersecurity incident occurred. Overall, positives around growth, profitability, product adoption and clinical validation substantially outweighed the challenges.View all ISRG earnings summariesISRG Revenue Breakdown
67.72% U.S.
32.28% Outside of U.S
ISRG Stock 12 Month Forecast
Average Price Target
$576.53
▲(22.87% Upside)
Technical Analysis
Ownership Overview
0.47% Insiders
22.31% Mutual Funds
8.75% Other Institutional Investors
42.51% Public Companies and Individual Investors